Report Code: TIPMD00002573 | No. of Pages: 150 | Category: Medical Device | Status: Upcoming
Exocrine Pancreatic Insufficiency (EPI) is a type of medical condition where the pancreas are not able to produce sufficient digestive enzymes, leading to malabsorption of nutrients and malnutrition. EPI can be caused by various factors, including chronic pancreatitis, pancreatic cancer, and cystic fibrosis. EPI is commonly treated with enzyme replacement therapy (ERT), which replaces the missing digestive enzymes with oral supplements. ERT is an effective way to improve nutrient absorption and alleviate symptoms, making it a valuable treatment option for people with EPI. The end-users of EPI treatments are typically individuals who have been diagnosed with EPI, as well as healthcare providers who prescribe these treatments. ERT is an important tool for preventing malnutrition and enhancing quality of life for people with EPI. The future of the EPI market looks promising, driven by the growing recognition of the benefits of ERT, and advancements in treatment options.
The "Global Exocrine Analysis To 2028" is a specialized and in-depth study of the medical device industry with a focus on the exocrine trend. The report aims to provide an overview of global exocrine with detailed market segmentation by type, end user and geography. The global exocrine is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading market players and offers key trends and opportunities in the exocrine.
The global anesthesia machines market is segmented on the basis of product and end user. The product segment includes stand-alone anesthesia machines and portable anesthesia machines. Based on end user, the exocrine pancreatic insufficiency market is classified as, hospitals, clinics, and ambulatory surgical centers.
The exocrine pancreatic insufficiency market is likely to anticipate grow with a significant rate in the forecast years, owing to driving factors such as, rise in the prevalence of gastrointestinal disorders, ulcerative colitis, and small intestinal bacterial growth among others. In addition, increasing prevalence of the cystic fibrosis, pancreatic cancer, diabetes are likely to grow the market in the forecast years. The market is likely to seek various opportunities to develop easy test and innovative products to treat the exocrine pancreatic insufficiency.
The global exocrine pancreatic insufficiency market is segmented on the basis of type and end user. On the basis type segment includes imaging and sample test. The imaging segment is further divided into sub-segments such as CT scanning, endoscopic ultra-sonography (EUS), magnetic resonance imaging (MRI) and others. Similarly, the sample test is further divided into blood test, fecal test and pancreatic function test. On the basis of the end user the segment is classified as hospitals, diagnostic laboratories, and others.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global exocrine pancreatic insufficiency market based on type, end user and geography. It also provides market size and forecast till 2028 for overall exocrine pancreatic insufficiency market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 13 counties globally along with current trend and opportunities prevailing in the region.
North America is expected to contribute to the largest share in the exocrine pancreatic insufficiency market in the coming years, owing to factors such as, rise in the incidences of the bacterial infection, rise in the prevalence of the exocrine pancreatic insufficiency and more. The Europe and Asia Pacific market is anticipated to hold large market share following the North America. The rise in the geriatric population across these regions are likely to contribute to the significant growth rate for the market.
The report also includes the profiles of key exocrine pancreatic insufficiency market manufacturing companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, products and services offered, financial information of last 3 years, key development in past five years. Some of the key players influencing the market are Medtronic, General Electric Company, Koninklijke Philips N.V., Siemens Healthcare GmbH, Canon Medical Systems, USA, ThermoFisher Scientific Inc., ScheBo Biotech AG, Hologic Inc., Immunostics, Inc. and Biohit Oyj.
The List of Companies
2. General Electric Company
3. Koninklijke Philips N.V.
4. Siemens Healthcare GmbH
5. Canon Medical Systems, USA
6. ThermoFisher Scientific Inc.
7. ScheBo Biotech AG
8. Hologic Inc.
9. Immunostics, Inc.
10. Biohit Oyj